2024
The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study.
Althoff K, Stewart C, Humes E, Gerace L, Boyd C, Gebo K, Justice A, Hyle E, Coburn S, Lang R, Silverberg M, Horberg M, Lima V, Gill M, Karris M, Rebeiro P, Thorne J, Rich A, Crane H, Kitahata M, Rubtsova A, Wong C, Leng S, Marconi V, D'Souza G, Kim H, Napravnik S, McGinnis K, Kirk G, Sterling T, Moore R, Kasaie P. The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. PLOS Medicine 2024, 21: e1004325. PMID: 38215160, PMCID: PMC10833859, DOI: 10.1371/journal.pmed.1004325.Peer-Reviewed Original ResearchConceptsHistory of injection drug useInjection drug useHealthcare needsPrevalence of comorbiditiesHIV diagnosisNorth American AIDS Cohort CollaborationDrug useAntiretroviral therapyHIV surveillance dataGuideline-recommended careNon-Hispanic whitesPrevalence of anxietyChronic kidney diseaseMyocardial infarctionPrevalence of cancerEnd-stage liver diseaseResearch and DesignMultimorbidity prevalenceRisk of comorbiditiesUnited StatesBlack MSMNon-HispanicSubspecialty careClinical capacityHIV clinicians
2022
Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV
Kim HN, Nance RM, Re V, Silverberg MJ, Franco R, Sterling TR, Cachay ER, Horberg MA, Althoff KN, Justice AC, Moore RD, Klein M, Crane HM, Delaney JA, Kitahata MM. Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 89: 396-404. PMID: 35202048, PMCID: PMC8887786, DOI: 10.1097/qai.0000000000002886.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseLiver diseaseNorth American AIDS Cohort CollaborationStandardized medical record reviewAccessible clinical parametersHIV-specific factorsChronic hepatitis BFibrosis-4 indexMedical record reviewSpontaneous bacterial peritonitisHarrell's C-statisticHepatitis B virusHepatitis C virusAlcohol use disorderRisk prediction modelRace/ethnicityCohort CollaborationESLD riskHepatic impairmentVariceal bleedHepatitis BBacterial peritonitisHepatic encephalopathyRecord reviewClinical parameters
2019
Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies
Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, Lucas GM, Klein MB, Kitahata MM, Crane H, Silverberg MJ, Gill MJ, Mathews WC, Dubrow R, Horberg MA, Rabkin CS, Klein DB, Re V, Sterling TR, Desir FA, Lichtenstein K, Willig J, Rachlis AR, Kirk GD, Anastos K, Palella FJ, Thorne JE, Eron J, Jacobson LP, Napravnik S, Achenbach C, Mayor AM, Patel P, Buchacz K, Jing Y, Gange SJ, Research and Design N. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. The Lancet HIV 2019, 6: e93-e104. PMID: 30683625, PMCID: PMC6589140, DOI: 10.1016/s2352-3018(18)30295-9.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseEnd-stage renal disease outcomesPopulation attributable fractionRenal disease outcomesTraditional risk factorsElevated total cholesterolLiver diseaseMyocardial infarctionRisk factorsRenal diseaseTotal cholesterolDisease outcomeHIV RNANorth American AIDS Cohort CollaborationDetectable plasma HIV RNALow CD4 cell countsHepatitis B virus infectionEnd-stage renal diseaseClinical AIDS diagnosisDetectable HIV RNAHIV Clinical CohortLow CD4 countCD4 cell countPlasma HIV RNAB virus infection
2017
Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States
Wong C, Gange SJ, Moore RD, Justice AC, Buchacz K, Abraham AG, Rebeiro PF, Koethe JR, Martin JN, Horberg MA, Boyd CM, Kitahata MM, Crane HM, Gebo KA, Gill MJ, Silverberg MJ, Palella FJ, Patel P, Samji H, Thorne J, Rabkin CS, Mayor A, Althoff KN, Freeman A, Cescon A, Rachlis A, Rogers B, Rodriguez B, Grasso C, Benson C, Drozd D, Fiellin D, Haas D, Kirk G, Willig J, Globerman J, Brooks J, Eron J, Montaner J, Gabler K, Anastos K, Mayer K, Jacobson L, Kopansky-Giles M, Klein M, Turner M, Mugavero M, Saag M, Harrigan P, Dubrow R, Hunter-Mellado R, Hogg R, Bosch R, McKaig R, Bebawy S, Rourke S, Napravnik S, Boswell S, Sterling T. Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases 2017, 66: 1230-1238. PMID: 29149237, PMCID: PMC5889007, DOI: 10.1093/cid/cix998.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBlack PeopleCohort StudiesDiabetes Mellitus, Type 2FemaleHeterosexualityHIVHIV InfectionsHomosexuality, MaleHumansHypercholesterolemiaHypertensionLongitudinal StudiesMaleMiddle AgedMultimorbidityRenal Insufficiency, ChronicSexual and Gender MinoritiesUnited StatesWhite PeopleConceptsHuman immunodeficiency virusAdjusted prevalence ratiosAge-associated conditionsImmunodeficiency virusMultimorbidity prevalenceClinical careNorth American AIDS Cohort CollaborationEnd-stage liver diseaseMedian baseline ageHIV outpatient clinicChronic kidney diseaseRobust error varianceConfidence intervalsComplex healthcare needsDemographic subgroupsCohort CollaborationComorbidity preventionCohort studyDiabetes mellitusLiver diseaseOutpatient clinicKidney diseasePrevalence ratiosBaseline ageCare complexity
2016
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras
Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R, Research and Design of IeDEA F, Kirk G, Benson C, Bosch R, Boswell S, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Cescon A, Samji H, Brooks J, Buchacz K, Gebo K, Moore R, Moore R, Rodriguez B, Horberg M, Silverberg M, Thorne J, Goedert J, Jacobsonc L, D'Souza G, Klein M, Rourke S, Burchell A, Rachlis A, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Patel P, Brooks J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Kim H, Drozd D, Sterling T, Haas D, Bebawy S, Turner M, Justice A, Dubrow R, Fiellin D, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, Althoff K, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Drozd D, Morton L, McReynolds J, Lober W, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Wong C, Hogan B, Tong W, Liu B. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clinical Infectious Diseases 2016, 63: 1160-1167. PMID: 27506682, PMCID: PMC5064164, DOI: 10.1093/cid/ciw531.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseUse of antiretroviralsESLD riskAntiretroviral therapyLiver diseaseNorth American AIDS Cohort CollaborationTime-updated CD4 cell countModern antiretroviral therapy (ART) eraAntiretroviral therapy eraTenofovir-based regimensCD4 cell countModern antiretroviral therapyHuman immunodeficiency virusIncidence rate ratiosRate ratioCohort CollaborationCoinfected PersonsTherapy eraHCV therapyHIV RNAHepatitis BHepatitis statusImmunodeficiency virusC virusAntiretroviral era
2015
Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
Re V, Kallan MJ, Tate JP, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park LS, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR. Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Open Forum Infectious Diseases 2015, 2: ofv109. PMID: 26284259, PMCID: PMC4536329, DOI: 10.1093/ofid/ofv109.Peer-Reviewed Original ResearchEnd-stage liver diseaseHIV/HCV-coinfected patientsRisk of ESLDHIV/HCV patientsHuman immunodeficiency virusFIB-4Antiretroviral therapyESLD riskHCV patientsLaboratory variablesLiver diseaseHuman immunodeficiency virus/hepatitis C virus‐coinfected patientsHepatitis C virus-coinfected patientsLiver-related deathRetrospective cohort studyRisk factor modificationPlatelet ratio indexDecision curve analysisVeterans Health AdministrationHCV treatment decisionsHepatic decompensationHCV treatmentCohort studyCox regressionImmunodeficiency virus
2013
Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans
Anderson JP, Tchetgen E, Re V, Tate JP, Williams PL, Seage GR, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC. Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans. Clinical Infectious Diseases 2013, 58: 719-727. PMID: 24285848, PMCID: PMC3922212, DOI: 10.1093/cid/cit779.Peer-Reviewed Original ResearchConceptsHepatitis C virusInitiation of ARTAntiretroviral therapyHepatic decompensationHazard ratioVeterans Aging Cohort Study Virtual CohortHIV/HCV-coinfected patientsHuman immunodeficiency virus (HIV) coinfectionEnd-stage liver diseaseHepatic decompensation eventsIncident hepatic decompensationLiver disease outcomesCombination antiretroviral therapyImmunodeficiency virus coinfectionHospital discharge diagnosisSpontaneous bacterial peritonitisCopies/mLMarginal structural modelsART initiationART regimenDecompensation eventsHIV RNAVariceal hemorrhageBacterial peritonitisLiver failure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply